Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study.
Olga Amengual,Ricardo Forastiero,Mayumi Sugiura-Ogasawara,Kotaro Otomo,Kenji Oku,C. Favas,J. Delgado Alves,P Žigon,A Ambrožič,Matija Tomšič,Ioana Ruiz-Arruza,Guillermo Ruiz-Irastorza,Maria Laura Bertolaccini,Gary L. Norman,Zakera Shums,J. Arai,Atsuko Murashima,Anne E. Tebo,Maria Gerosa,Pier Luigi Meroni,Ignasi Rodríguez-Pintó,Ricard Cervera,J. Swadzba,Jacek Musiał,Tatsuya Atsumi +24 more
TL;DR: IgG aPS/PT detection is an easily performed laboratory parameter that might contribute to a better and more complete identification of patients with APS.
read more
Abstract: ObjectiveA task force of scientists at the International Congress on Antiphospholipid Antibodies recognized that phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) might contribute to a better identification of antiphospholipid syndrome (APS). Accordingly, initial and replication retrospective, cross-sectional multicentre studies were conducted to ascertain the value of aPS/PT for APS diagnosis.MethodsIn the initial study (eight centres, seven countries), clinical/laboratory data were retrospectively collected. Serum/plasma samples were tested for IgG aPS/PT at Inova Diagnostics (Inova) using two ELISA kits. A replication study (five centres, five countries) was carried out afterwards.ResultsIn the initial study (n = 247), a moderate agreement between the IgG aPS/PT Inova and MBL ELISA kits was observed (k = 0.598). IgG aPS/PT were more prevalent in APS patients (51%) than in those without (9%), OR 10.8, 95% CI (4.0–29.3), p < 0.0001. Sensitivity, specificity, positive (LR+) and negative (LR...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances
TL;DR: This Review focuses on the current classification criteria for APS, presenting the role of extra-criteria manifestations and lab-based tests, and Diagnostic approaches to difficult cases, including so-called seronegative APS.
180
The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS
Thomas McDonnell,Chris Wincup,Ina Buchholz,Charis Pericleous,Ian Giles,Vera M. Ripoll,Hannah Cohen,Mihaela Delcea,Anisur Rahman +8 more
TL;DR: Beta-2-Glycoprotein I is a unique protein with a key role in haemostasis, homeostasis and immunity and how these factors may influence its contribution to disease pathogenesis is examined.
121
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis.
Roberto Giacomelli,Antonella Afeltra,Alessia Alunno,E Bartoloni-Bocci,Onorina Berardicurti,Michele Bombardieri,Alessandra Bortoluzzi,Roberto Caporali,Francesco Caso,Ricard Cervera,Maria Sole Chimenti,Paola Cipriani,Emmanuel Coloma,Fabrizio Conti,Salvatore D'Angelo,Salvatore De Vita,Salvatore Di Bartolomeo,Oliver Distler,Andrea Doria,Eugen Feist,Benjamin A Fisher,Maria Gerosa,Michele Gilio,Giuliana Guggino,Vasiliki Liakouli,Domenico Paolo Emanuele Margiotta,Pier Luigi Meroni,Gianluca Moroncini,Federico Perosa,Marcella Prete,Roberta Priori,Chiara Rebuffi,Piero Ruscitti,Raffaele Scarpa,Yehuda Shoenfeld,Monica Todoerti,Francesco Ursini,Guido Valesini,Serena Vettori,Claudio Vitali,Athanasios G. Tzioufas +40 more
TL;DR: The overarching aim of this work was to clarify the meaning of specific biomarkers during autoimmune diseases; their possible role in confirming diagnosis, predicting outcome and suggesting specific treatments.
119
Antiphosphatidylserine/Prothrombin Antibodies: An Update on Their Association with Clinical Manifestations of Antiphospholipid Syndrome.
Massimo Radin,Silvia Grazietta Foddai,Irene Cecchi,Elena Rubini,Karen Schreiber,Karen Schreiber,Dario Roccatello,Maria Laura Bertolaccini,Savino Sciascia +8 more
TL;DR: With the available level of evidence, aPS/PT testing can be considered as a robust test applicable in the investigation of patients suspected for APS, also beyond the research settings.
45
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements
Polona Žigon,Anuška Podovšovnik,A. Ambrožič,Matija Tomšič,Matija Tomšič,Alojzija Hočevar,N. Gašperšič,Žiga Rotar,Sonja Praprotnik,Snežna Sodin Šemrl,Snežna Sodin Šemrl,Saša Čučnik,Saša Čučnik +12 more
TL;DR: The aims of this cross-sectional, retrospective study of consecutive autoimmune patients’ samples were to evaluate the association of non-criteria antiphospholipid antibodies (aPL) with thrombosis and obstetric events, to calculate the risk score for adverse events and to assess the specific contribution of single aPL positivity in SN-APS.
36
References
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
Spiros Miyakis,Michael D. Lockshin,Tatsuya Atsumi,D W Branch,Robin L. Brey,Ricard Cervera,R. H. W. M. Derksen,P. G. De Groot,Takao Koike,Pier Luigi Meroni,Guido Reber,Yehuda Shoenfeld,Angela Tincani,Panayiotis G. Vlachoyiannopoulos,Steven A. Krilis +14 more
TL;DR: This document appraise the existing evidence on clinical and laboratory features of APS addressed during the forum and proposes amendments to the Sapporo criteria, including definitions on features ofAPS that were not included in the updated criteria.
6.7K
Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
TL;DR: The detection of lupus anticoagulants and, possibly, of immunoglobulin G (IgG) anticardiolipin antibodies at medium or high titers helps to identify patients at risk for thrombosis, however, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods.
1K
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
TL;DR: The value of the classic assays LAC and ACA to detect aPL associated with thrombotic complications is compared with new assays which are based on the binding of aPL to the plasma proteins prothrombin and beta 2GPI, and it is shown that the LAC assay correlates best with a history of both arterial and venousThrombosis.
277
Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.
Savino Sciascia,Giovanni Sanna,Veronica Murru,Dario Roccatello,Munther A. Khamashta,Maria Laura Bertolaccini +5 more
TL;DR: Routine measurement of aPS/PT (but not aPT) might be useful in establishing the thrombotic risk of patients with previousThrombosis and/or systemic lupus erythematosus and their inclusion as laboratory criteria for the APS should be indisputable further explored.
β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome
TL;DR: It is suggested that anti-beta(2)-glycoprotein I antibodies with LAC activity are antibodies that are responsible for the thromboembolic complications in the antiphospholipid syndrome.
233